| Evidence domain | Direct SMD-A finding | Evidence type/publication | Confidence and limitations |
|---|---|---|---|
| Original delineation | SMD-A was introduced after evaluation of five affected individuals from an Algerian family. | Human case series: Kozlowski et al., *Pediatric Radiology* (1988), DOI: [10.1007/BF02390399](https://doi.org/10.1007/BF02390399) (pqac-00000001) | **Moderate:** Foundational disease-specific evidence, but only five related cases; detailed individual-level data were unavailable in the retrieved text. |
| Defining phenotype | Core findings are short trunk and severe genu valgum, with moderate platyspondyly—especially dorsal vertebral flattening—short ilia, narrow greater sciatic notches, and generalized metaphyseal dysplasia of the long bones. | Disease-specific synthesis of the original phenotype: Zhang et al., *Clinical Genetics* (2020), DOI: [10.1111/cge.13680](https://doi.org/10.1111/cge.13680) (pqac-00000018) | **Moderate:** The clinicoradiographic pattern is characteristic, but frequencies, penetrance, and longitudinal progression cannot be estimated from the very small cohort. |
| Molecular etiology | A 7-year-old Japanese boy with an SMD-A-matching phenotype carried heterozygous **COL2A1** NM_001844.4:c.2582G>T, p.(Gly861Val), supporting classification as an autosomal-dominant type II collagenopathy. | Human molecular case report: Matsubayashi et al., *Molecular Syndromology* (2013), 4:148–151 (pqac-00000008, pqac-00000018) | **Moderate:** Disease-specific genotype–phenotype evidence, but based on one molecularly characterized case; no SMD-A-specific functional assay was reported, and the 2020 review described the classification as supportive rather than definitive. |
| Overlapping phenotype context | Six patients with a related **COL2A1** phenotype shared disproportionate short stature, platyspondyly, shortened long bones, epiphyseal and hip dysplasia, metaphyseal dappling and corner-fracture lesions, and genu varum or valgum. Reported substitutions were Gly154Arg in two patients, Gly181Arg, Gly922Arg, Gly861Val, and Gly546Ser. | Human comparative case synthesis: Chen et al., *BMC Pediatrics* (2017), DOI: [10.1186/s12887-017-0930-9](https://doi.org/10.1186/s12887-017-0930-9) (pqac-00000004, pqac-00000005) | **Low for strict SMD-A assignment; moderate for phenotypic overlap:** The authors classified this pattern as an SEMD-Strudwick variant; corner-fracture and dappling findings should not automatically be equated with classic SMD-A. |
| Broader COL2A1 evidence | Across 663 probands, investigators catalogued 460 distinct **COL2A1** variants and 21 disorders; 488 of 663 variants (73.6%) were substitutions, 439 of 539 coding-region variants lay in the triple-helical domain, and 140 substitutions replaced glycine. | Aggregated literature and LOVD analysis: Zhang et al., *Clinical Genetics* (2020), DOI: [10.1111/cge.13680](https://doi.org/10.1111/cge.13680) (pqac-00000019, pqac-00000020) | **High for the broader type II collagenopathy spectrum, not SMD-A prevalence:** Database ascertainment and phenotype-label uncertainty limit genotype–phenotype inference; these statistics are not SMD-A-specific. |
| Glycine-substitution mechanism | Glycine substitutions in Gly-X-Y repeats commonly destabilize the collagen-II triple helix and are generally interpreted as dominant-negative structural variants; glycine replacement accounted for 142 of 415 (34%) catalogued variants. | Mutation review and database synthesis: Barat-Houari et al., *Human Mutation* (published online October 7, 2015; issue 2016), DOI: [10.1002/humu.22915](https://doi.org/10.1002/humu.22915) (pqac-00000009, pqac-00000011) | **High as a general collagen-II model; inferred for p.Gly861Val:** Variant position does not reliably predict phenotype, and genetic, epigenetic, or environmental modifiers remain possible. |
| Contemporary mechanistic model | A human isogenic iPSC-cartilage model of another dominant **COL2A1** glycine substitution, p.Gly1170Ser, showed slow procollagen-II folding and secretion with intracellular ER accumulation but no coupled unfolded-protein response. | Human in-vitro preprint, version posted March 9, 2024: Yammine et al., bioRxiv, DOI: [10.1101/2023.10.19.562780](https://doi.org/10.1101/2023.10.19.562780) (pqac-00000013) | **Indirect and hypothesis-generating only:** This is a different variant and phenotype, and the cited version was not peer reviewed. It does not establish ER storage or absent UPR activation in p.Gly861Val SMD-A; reviews emphasize mutation-, collagen-, and cell-specific responses (pqac-00000014, pqac-00000015). |


*Table: Evidence tiers supporting the clinical definition and COL2A1 association of SMD-A, while distinguishing direct disease observations from overlapping phenotypes and indirect mechanistic models.*